One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
You may also be interested in...
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).